

## SUPPLEMENTARY TABLES

**Table S1: Sensitivity analysis: Comparison of the results of ITT analysis with per protocol analyses**

	N (int) *	N (usual care)*	Total	Mean	SD	Min - Max	Difference in means 95% CI	p-value
<b>ITT</b>	424	463	887	12.79	6.64	0 - 35	-1.81 (-2.66, -0.95)	<0.001
<b>Per protocol 1:</b> Including all in the usual care arm and those in the intervention who received the intervention booklet and had 3 follow-up contacts	391	463	854	12.84	6.67	0 - 35	-1.84 (-2.70, -0.99)	<0.001
<b>Per protocol 2:</b> Including all in the usual care arm and those in the intervention who received the intervention booklet and had 2 follow-up contacts	24	463	487	13.76	6.80	0 - 32	-0.83 (-3.16, 1.50)	0.485
<b>Per protocol 3:</b> Including all in the usual care arm and those in the intervention who received the intervention booklet and had 1 follow-up contact	5	463	468	13.88	6.85	0 - 32	-0.57 (-5.12, 3.99)	0.807
<b>Per protocol 4:</b> Including all in the usual care arm and those in the intervention who received the intervention booklet and had no follow-up contacts	2	463	465	13.90	6.83	0 - 32	-4.25 (-11.38, 2.89)	0.244
<b>Per protocol 5:</b> Including all in the usual care arm and those in the intervention who received the intervention in the protocolised format (all 3 follow-ups, week 1 was delivered on the phone and week 4 or 12 delivered in the participants preferred follow-up method (not done face-to-face))	344	463	807	12.83	6.63	0-35	-2.06 (-2.92, -1.20)	<0.001

\*Ns included in analysis (dependent on completion of IPSS at baseline and 12 month follow-up)

**Table S2: Reasons for exclusion at GP manual screening**

<b>Reason for exclusion</b>	<b>Patients excluded at GP manual screening; n (% of all exclusions)</b>
<i>Currently being treated for prostate or bladder cancer</i>	50 (2.4)
<i>Lack of capacity</i>	85 (4.2)
<i>Patient does not have LUTS</i>	871 (42.6)
<i>Patient is under 18 years of age</i>	4 (0.2)
<i>Patient has poorly-controlled diabetes mellitus</i>	18 (0.9)

<i>Previous prostate surgery</i>	71 (3.5)
<i>Recently referred or currently under urological review</i>	441 (21.5)
<i>Relevant neurological disease or referral</i>	56 (2.7)
<i>Unable to complete assessments in English</i>	9 (0.4)
<i>Unable to pass urine without a catheter</i>	61 (3.0)
<i>Undergoing urological testing for LUTS</i>	38 (1.9)
<i>Visible haematuria</i>	42 (2.1)
<i>Other*</i>	301 (14.7)
	2,047

*\*Other: Awaiting surgery or had previous surgery (n=2), COPD (n=3), cancer (n=17), cognitive impairment (n=14), deceased (n=4), declined research (n=6), declined treatment for LUTS (n=4), under palliative care (n=6), family bereavement/illness (n=6), frail (n=39), housebound (n=19), may not be able to comply with follow-up (n=2), mental health or substance use issues (n=29), no symptoms (n=13), not living at home (n=17), no longer at practice (n=13), involved in another trial (n=50), permanent catheter (n=1), prostatitis (n=3), UTI (n=6), under bladder/bowel services (n=1), reason not given (n=9) and other (n=37).*



**Table S3 Serious Adverse Events (identified through trial SAE reporting procedures)**

	Received Intervention	Received Usual care	Overall
<b><i>Adverse events</i></b>			
Total number of SAEs; n	47	47	94
Total number of related AEs; n	0	0	0
Total number of deaths; n	2	1	3
<b><i>Status of SAEs; n(%)<sup>a</sup></i></b>			
Resolved	45 (95.74%)	44 (93.62%)	89
Ongoing	0	2 (4.26%)	2
Died	2 (4.26%)	1 (2.13%)	3

<sup>a</sup> Denominator for the proportion is the total number of SAEs in treatment arm